Bg

TYPE II COLLAGEN

UC-II® supplies collagen with undenatured type-ll collagen for joint function support. It is manufactured in the United States through a patented, low-temperature, non-enzymatic process. Four clinical studies show that the benefits of 40 mg of UC-ll® are joint comfort, mobility and flexibility.1

  • Small and effective 40 mg dose
  • Self-Af rmed GRAS
  • NDI - FDA noti ed and published NDIs
  • Made in the USA in a GMP- certi ed facility

UC-II® is a natural ingredient which contains a glycosylated, undenatured type-II collagen from chicken sternum.1 Previous studies have shown that small doses of UC-II modulate joint function in both OA and RA.1

UC-ll® is so effective you only need a small amount of this undenatured form of type ll collagen once-a-day to support joint comfort. Recent research suggests that UC-II® is significantly better than glucosamine + chondroitin.1

WHAT IS NATIVE COLLAGEN?

Collagens are the most abundant family of proteins in the extracellular matrix of connective tissues. Structure of native collagen: characteristic triple helix of three polypeptide chains rich in Gly, Pro and Hyp.

Based on their supramolecular organization, 26 different types of collagen have been described. Besides its biomechanical properties, collagens have other functions which are strongly dependant on the supramolecular triple helix structure: Cellular differentiation and gene expression, Cell attachment and migration, Tissue homeostasis regulation.2

NATIVE COLLAGEN STRUCTURE

Image

UCII®
CLINICAL
TRIALS

Significantly more effective

Statistically significantly more effective than
glucosamine plus chondroitin as measured by WOMACK

Image

Lugo JP, et al. Ef cacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo- controlled study. Nutr J. 2016;15:14.

Clinically Studied in
Healthy, Active Adults

Average Knee Extension in Healthy Subjects

Image

Lugo JP, et al. Undernatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr. 2013;10:48.

MORE UCII®
CLINICAL TREIALS

Effects of oral administration of type II collagen on rheumatoid arthritis. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Ha er DA, Weiner HL. Department of Medicine, Beth Israel Hospital, Boston, MA. Science. 1993 Sep 24;261(5129):1727-30.

Effects of orally administered undenatured type II collagen against arthritic in ammatory diseases: a mechanistic exploration. Bagchi D, Misner B, Bagchi M, Kothari SC, Downs BW, Fafard RD, Preuss HG. Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University Medical Center, Omaha, Nebraska 68178, USA.

Treatment of rheumatoid arthritis by oral administration of bovine tracheal type II collagen. Ausar SF, Beltramo DM, Castagna LF, Quintana S, Silvera E, Kalayan G, Revigliono M, Landa CA, Bianco ID. CEPROCOR (Centro de Excelencia en Productos y Procesos de Córdoba), Argentina. Rheumatol Int. 2001 May;20(4):138-44.

Control of rheumatoid arthritis by oral tolerance. Choy EH, Scott DL, Kingsley GH, Thomas S, Murphy AG, Staines N, Panayi GS. Guy’s Kings, Hospital School of Medicine, King’s College, London, UK. Arthritis Rheum. 2001 Sep;44(9):1993-7.

UCII®
Unique Mechanism of Action1

The etiology behind UC-II’s impact on OA symptoms is not known. However, undenatured type II collagen has been shown to protect animals against the onset of joint damage in both OA and RA experimentally induced arthritis models. This protection is hypothesized to occur via the induction and migration of T-regulatory cell (Tregs) to the area of inflammation and damage. The proposed role of Tregs may also have relevance to the moderation of OA symptoms, as in vitro studies have found that Tregs produce anti-inflammatory cytokines that stimulate chondrocytes to synthesize cartilage matrix components.

Oral tolerance (OT) is consists of the oral administration of antigens (Ag) that could alter the response of the immune system. This is a form of peripheral immune tolerance in which mature lymphocytes in the peripheral lymphoid tissues are rendered non-functional or hyporesponsive by prior oral administration of Ag. This therapeutic approach requires the orally administration of Ag and the active participation of the gut-associated lymphoid tissue (GALT), a tissue comprising Peyer’s patches, intraepitelial cells and villi containing epithelials cells which is a well organized immune network. The mechanisms by which OT is mediated included deletion or anergy and active cellular suppression. The primary factor determining which form of tolerance will be developed after oral administration of Ag is the Ag dosage. Thus, it is thought that low doses of Ag induce the generation of active suppression, via regulatory T cells in the GALT, which then migrate to the systemic immune system. These regulatory T cells produce down-regulatory cytokine pattern.

1 REFERENCES:

Lugo JP, et al. Ef cacy and tolerability of an unde- natured type II collagen supplement in modula- ting knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14.

Lugo JP, et al. Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-cont- rolled study in healthy volun- teers. J lnt Soc Sports Nutr. 2013;10:48.

Bagi C.M. Osteoarthritis - Opportunities for nonsurgical therapies. Pre- sented at 8th International Conference of Orthopedic Surgeons and Rheumatology, March 22-23, 2017 Rome, Italy.

Oral tolerance in the treat- ment of rheumatoid arthritis. Toussirot EA. Department of Rheumatology, University Hospital Jean Minjoz, Bd A. Fleming, F- 25030 Besançon Cédex, France. eric.toussi- rot@ufc-chu.univ-fcomte.fr Curr Drug Targets In amm Allergy. 2002 Mar;1(1):45-52.

Collagen in the treatment of rheumatic diseases--oral tolerance. Stancikova M, Stancik R, Gubzova Z, Ro- vensky J. Research Institute of Rheumatic Diseases, Pi- estany, Slovakia. stanciko- va@vurch.sk Bratisl Lek Listy. 1999;100(10):567-71.

Control of rheumatoid arthritis by oral tolerance. Choy EH, Scott DL, Kingsley GH, Thomas S, Murphy AG, Staines N, Panayi GS. Guy’s Kings, Hospital School of Medicine, King’s College, London, UK. Arthritis Rheum. 2001 Sep;44(9):1993-7. Oral tolerance Howard L. Weiner,1 Andre Pires da Cunha,1 Francisco Quintana,1 and HenryWu1,*

SAFETY PROFILE Marone PA, et al. Safety and toxicological evalua- tion of undenatured type II collagen. Toxicol Mech Meth. 2010;20:175-189.

Image

UCII® is registered trademark of Lonza Inc. 90 Boroline Road Allendale, NJ 07401 USA
Above informations and statements are adopted from the official data of UCII®,
by permission of Lonza Inc.

headquarter and distribution

Headquarter and Distribution

Research and Manufacturing

Research and Manufacturing

Sales and Marketing

Sales and Marketing

Synergo Lab